IASLC TTLC 2022 | Lineage plasticity in EFGR-mutant lung cancer

Ryan Gentzler, MD, University of Virginia, Charlottesville, VA, provides an overview of current research on lineage plasticity in lung cancer. Lineage plasticity, which involves cancer cells changing cell type, can be a mechanism of resistance to immunotherapies and targeted therapies in 5-10% of patients with EFGR-mutant lung cancer. Biopsies can detect lineage plasticity in cells, and whilst more research is required to overcome this, current options in small cell lung cancer (SCLC) include platinum- or etoposide-based chemotherapies. This interview took place at the 2022 Targeted Therapies of Lung Cancer Meeting (TTLC22).